
An allogeneic platform designed to generate First-In-Class Tumors antigen-focused immunotherapies.
Changing a paradigm in oncology
Our mission at Brenus is to fight relapsing diseases in cold solid tumors, which is currently the biggest unmet need in oncology.
The efficacy of current approaches is compromised by no anticipating tumor plasticity and resistances mechanisms and must be combined to be efficient.
Strict and AI assisted selection of Specific allogeneic Tumor cell lines to be the most representative of the targeted indication.
Selection criteria of starting material (Allogeneic tumor cell lines)
Our STC manufacturing overpasses current approaches by covering a broad & higher-quality range of tumor antigens.
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens
Haptenization process is a proven immunogenic tagging** sustainably boosting antigen’s immune recognition. It’s safely ensure immune system activation.
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets